How to modify 7-azaindole to form cytotoxic Pt(II) complexes: highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22922312
DOI
10.1016/j.jinorgbio.2012.05.006
PII: S0162-0134(12)00174-2
Knihovny.cz E-resources
- MeSH
- Cisplatin * analogs & derivatives chemical synthesis chemistry pharmacology MeSH
- Cytotoxins * chemical synthesis chemistry pharmacology MeSH
- Indoles chemistry MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Neoplasms drug therapy metabolism MeSH
- Antineoplastic Agents * chemical synthesis chemistry pharmacology MeSH
- RNA, Neoplasm biosynthesis MeSH
- RNA biosynthesis MeSH
- Drug Screening Assays, Antitumor methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- 7-azaindole dimer MeSH Browser
- Cisplatin * MeSH
- Cytotoxins * MeSH
- Indoles MeSH
- Antineoplastic Agents * MeSH
- RNA, Neoplasm MeSH
- RNA MeSH
The platinum(II) dichlorido and oxalato complexes of the general formula cis-[PtCl(2)(nHaza)(2)] (1-3) [Pt(ox)(nHaza)(2)] (4-6) involving 7-azaindole halogeno-derivatives (nHaza) were prepared and thoroughly characterized. A single-crystal X-ray analysis of cis-[PtCl(2)(3ClHaza)(2)]·DMF (1·DMF; 3ClHaza symbolizes 3-chloro-7-azaindole) revealed a distorted square-planar arrangement with both the 3ClHaza molecules coordinated through their N7 atoms in a cis fashion. In vitro cytotoxicity of the complexes was evaluated by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay against the HOS (osteosarcoma), MCF7 (breast adenocarcinoma) and LNCaP (prostate adenocarcinoma) human cancer cell lines. The dichlorido complexes 1-3 (IC(50)=3.8, 3.9, and 2.5 μM, respectively) showed significantly higher in vitro anticancer effect against HOS as compared with cisplatin, whose IC(50)=37.7 μM. The biological effect of cisplatin against MCF7 (IC(50)=24.5 μM) and LNCaP (IC(50)=3.8 μM) was also exceeded by 1-3 (except for 2 against LNCaP), but the difference can be classified as significant only in the case of 1 (IC(50)=3.4 μM) and 3 (IC(50)=2.0 μM) against MCF7. The molecular pharmacological studies (RNA synthesis by T7 RNA polymerase in vitro) proved that 1-3 bind to DNA in a similar manner as cisplatin, since the RNA synthesis products of 1-3 and cisplatin showed a similar sequence profile of major bands.
References provided by Crossref.org
In vitro anticancer active cis-Pt(II)-diiodido complexes containing 4-azaindoles
In Vitro Antitumor Active Gold(I) Triphenylphosphane Complexes Containing 7-Azaindoles
Gold(I) complexes of 9-deazahypoxanthine as selective antitumor and anti-inflammatory agents
Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives
N6-benzyladenosine derivatives as novel N-donor ligands of platinum(II) dichlorido complexes
5-Bromo-1H-pyrrolo-[2,3-b]pyridine